Assessing the usefulness of anticardiolipin antibody assays - A cautious approach is suggested by high variation and limited consensus in multilaboratory testing

被引:83
作者
Favaloro, EJ [1 ]
Silvestrini, R
机构
[1] WSAHS, Dept Haematol, ICPMR, Westmead, NSW 2145, Australia
[2] WSAHS, Dept Immunopathol, ICPMR, Westmead, NSW 2145, Australia
关键词
anticardiolipin antibody; antiphospholipid antibody; assay; laboratory assessment; quality assurance; antiphospholipid syndrome;
D O I
10.1309/JAMH-GDQ6-6BYK-DW6J
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
An anticardiolipin antibody (ACA) assay has become a laboratory standard for the detection of antiphospholipid antibodies. We evaluated data from a quality assurance program to assess ACA assay usefulness. Cross-laboratory (n = 56) testing of 12 serum samples yielded interlaboratory coefficients of variation (CVs)for IgG ACA and IgM ACA that were higher than 50% in 17 (71%) of 24 cases. The situation for testing consensus was of equal concern. Total consensus occurred in 6 (25%) of 24 cases. General consensus (interlaboratory agreement, 90% or more) was obtained in 10 (42%) of 24 cases. In the majority of test cases, laboratories could not agree on whether a serum sample tested was ACA-positive or ACA-negative. Differing method-related issues also were evident; some methods tended toward higher or lower ACA values. Method-based majority consensus differed from participant majority consensus on many test occasions. Exceedingly high interlaboratory result variation, combined with a general lack of test result grading consensus and method-based variation, indicate that a cautious clinical approach toward laboratory findings is prudent. Laboratory tests should be repeated at least once before making a clinical diagnosis of any anti-phospholipid syndrome-like disorder.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 19 条
[1]  
Court EL, 1997, BRIT J BIOMED SCI, V54, P287
[2]   Clinical utility of anticardiolipin antibody assays: High inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach [J].
Favaloro, EJ ;
Silvestrini, R ;
Mohammed, A .
PATHOLOGY, 1999, 31 (02) :142-147
[3]   Recent insights into antiphospholipid antibody-mediated thrombosis [J].
Field, SL ;
Brighton, TA ;
McNeil, HP ;
Chesterman, CN .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 1999, 12 (03) :407-422
[4]  
Galli M, 1997, THROMB HAEMOSTASIS, V78, P75
[5]   ANTIPHOSPHOLIPID ANTIBODIES AND VENOUS THROMBOEMBOLISM [J].
GINSBERG, JS ;
WELLS, PS ;
BRILLEDWARDS, P ;
DONOVAN, D ;
MOFFATT, K ;
JOHNSTON, M ;
STEVENS, P ;
HIRSH, J .
BLOOD, 1995, 86 (10) :3685-3691
[6]   ANTICARDIOLIPIN ANTIBODIES AND THE RISK FOR ISCHEMIC STROKE AND VENOUS THROMBOSIS [J].
GINSBURG, KS ;
LIANG, MH ;
NEWCOMER, L ;
GOLDHABER, SZ ;
SCHUR, PH ;
HENNEKENS, CH ;
STAMPFER, MJ .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :997-1002
[7]  
HARRIS EN, 1983, LANCET, V2, P1211
[8]   THROMBOSIS, RECURRENT FETAL LOSS, AND THROMBOCYTOPENIA - PREDICTIVE VALUE OF THE ANTICARDIOLIPIN ANTIBODY-TEST [J].
HARRIS, EN ;
CHAN, JKH ;
ASHERSON, RA ;
ABER, VR ;
GHARAVI, AE ;
HUGHES, GRV .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (11) :2153-2156
[9]  
HARRIS EN, 1986, CLIN EXP IMMUNOL, V68, P215
[10]  
HARRIS EN, 1990, BRIT J HAEMATOL, V70, P1